The iQ Group Global collaborates with Harvard University’s Wyss Institute to explore the feasibility of a real-time, printable COVID-19 diagnostic test

The iQ Group Global has entered into a material transfer agreement with Harvard University’s Wyss Institute to explore whether a proprietary technology developed at the Wyss Institute could be used to help provide a printable point-of-care SARS-CoV-2 antibody test for the COVID-19 disease that could produce results in real-time. Life Science Biosensor Diagnostics Pty Ltd […]

More

Explainer: Drug development, the regulatory process and the COVID-19 vaccine race

Athena Kolivos, Chief Scientific Officer CRC & Farmaforce The vaccine discovery and development experience unfolding for COVID-19 serves as a timely reminder that researching, developing and commercialising therapies to prevent, treat or cure life-threatening diseases is an extensive process; one that is very different from bringing everyday products and commodities to the marketplace. Across the […]

More

COVID-19 Q&A: Vaccine vs Antibody Test

In our series ‘COVID-19 Explained’, experts from The iQ Group Global demystify frequently asked questions about the COVID-19 virus.   This week, CRC and Farmaforce Chief Scientific Officer Athena Kolivos explains the difference between a vaccine and an antibody test, and why both are important in the fight against the COVID-19 pandemic.  What is a vaccine and […]

More

Cancer drug found to have ‘better staying power, reduced toxicity’ in preclinical trial – University of Texas at Austin

The below article was produced by The University of Texas at Austin and republished here with permission. UNIVERSITY OF TEXAS AT AUSTIN – A drug candidate has been found in preclinical trials to stop tumor growth entirely, deliver more cancer-busting power than many commonly used chemotherapy drugs and do so with fewer toxic side effects […]

More

The iQ Group Global Welcomes Dr. Jonathan Arambula as Vice President of Research, OncoTEX Inc.

The iQ Group Global, an enterprise dedicated to developing early stage bioscience assets, announced that Dr. Jonathan Arambula will join The iQ Group Global as the Vice President of Research, OncoTEX Inc. OncoTEX Inc. is a member company of The iQ Group Global that specializes in the development of oncology drugs. Its novel anticancer drug platform, TEX […]

More

World Renowned Professor of Chemistry, Professor Jonathan Sessler Appointed to the OncoTEX Inc. Board

One of the world’s most renowned Chemists and co-founder of the biopharmaceutical company, Pharmacyclics, Professor Jonathan L. Sessler has been appointed as a Non-Executive Director to the board of OncoTEX Inc., it was announced today. OncoTEX Inc. is a member company of The iQ Group Global that specializes in the development of oncology drugs. Its […]

More